Shire raises guidance on strong Q2
This article was originally published in Scrip
Shire has bounced back from a poor Q1 and upgraded its 2013 guidance following a strong set of Q2 numbers. "We anticipate that the rate of sales growth will continue to show improvement in the second half of this year, and we anticipate delivering full year, double digit non GAAP earnings growth," new CEO Flemming Ornskov said in a conference call. This is up from a previous guidance of "in line with consensus."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.